For years, the development of drugs for respiratory diseases, mainly asthma and chronic obstructive pulmonary disease (COPD), have relied on the administration of a new drug, mostly by inhalation and assessment by physiologic tests and questionnaires. More and more these new drugs are administered in fixed combinations.
This white paper outlines the latest respiratory R&D trends encompassing outcomes and clinical trial study designs.
Helpline Number
SGS House 4B, Adi Shankaracharya Marg, Vikhroli (West),
Mumbai, Maharashtra, 400 083,
India